Vaginal misoprostol administered at home after mifepristone (RU486) for abortion
- PMID: 9108832
Vaginal misoprostol administered at home after mifepristone (RU486) for abortion
Abstract
Background: There have been no US studies published on the effectiveness, safety, time to bleeding, and acceptability of misoprostol administered by vagina at home and repeated, if needed, after mifepristone was administered for abortion in women up to 8 weeks pregnant.
Methods: A prospective trial was conducted with women up to 8 weeks pregnant wanting an abortion. After receiving mifepristone 600 mg orally, subjects self-administered vaginal misoprostol 800 micrograms at home 2 days later. Subjects returned within 7 days, and if the gestational sac was still present on ultrasound, a repeat dose of misoprostol was administered in the office. Subjects completed a daily symptom log and a questionnaire on the acceptability of the procedures.
Results: Of the 166 subjects, 163 (98%) had a complete medical abortion. Three subjects presented with persistent bleeding and an incomplete abortion from 27 to 35 days after taking mifepristone and required surgical intervention. Vaginal spotting or bleeding occurred in 104 (62%) subjects before taking misoprostol, and 18 (11%) did not use misoprostol. Bleeding occurred on average 3.5 hours (SD, 3.2) after taking misoprostol. Six (4%) subjects required a second dose of misoprostol. Gastrointestinal side effects were common, mild, and brief. One hundred fifty-nine (96%) subjects agreed that the procedure went well, and 146 (90%) agreed that home administration of misoprostol was acceptable.
Conclusions: Two days after taking mifepristone, misoprostol administered by vagina was found to be safe, highly effective, and acceptable to women. Since only 6 subjects needed a second dose of misoprostol, conclusions about repeat doses are not possible. This procedure is a promising alternative to surgical abortion.
Comment in
-
Abortion procedure.J Fam Pract. 1997 Sep;45(3):193; author reply 194. J Fam Pract. 1997. PMID: 9299993 No abstract available.
-
Abortion procedure.J Fam Pract. 1997 Sep;45(3):193; author reply 194. J Fam Pract. 1997. PMID: 9299994 No abstract available.
-
Abortion procedure.J Fam Pract. 1997 Sep;45(3):193-4. J Fam Pract. 1997. PMID: 9299995 No abstract available.
-
Abortion procedure.J Fam Pract. 1997 Sep;45(3):194. J Fam Pract. 1997. PMID: 9299996 No abstract available.
Similar articles
-
Randomised controlled trial comparing the efficacy of same-day administration of mifepristone and misoprostol for termination of pregnancy with the standard 36 to 48 hour protocol.BJOG. 2007 Feb;114(2):207-15. doi: 10.1111/j.1471-0528.2006.01179.x. BJOG. 2007. PMID: 17305893 Clinical Trial.
-
Home self-administration of vaginal misoprostol for medical abortion at 50-63 days compared with gestation of below 50 days.Hum Reprod. 2010 May;25(5):1153-7. doi: 10.1093/humrep/deq037. Epub 2010 Feb 19. Hum Reprod. 2010. PMID: 20172871
-
Low-dose mifepristone 200 mg and vaginal misoprostol for abortion.Contraception. 1999 Jan;59(1):1-6. doi: 10.1016/s0010-7824(98)00150-4. Contraception. 1999. PMID: 10342079 Clinical Trial.
-
Prostaglandins for first-trimester termination.Best Pract Res Clin Obstet Gynaecol. 2003 Oct;17(5):745-63. doi: 10.1016/s1521-6934(03)00070-1. Best Pract Res Clin Obstet Gynaecol. 2003. PMID: 12972012 Review.
-
Comparison of vaginal and buccal misoprostol after mifepristone for medication abortion through 70 days of gestation: A retrospective chart review.Contraception. 2022 Nov;115:62-66. doi: 10.1016/j.contraception.2022.06.012. Epub 2022 Jun 28. Contraception. 2022. PMID: 35772525 Review.
Cited by
-
IMOP: randomised placebo controlled trial of outpatient cervical ripening with isosorbide mononitrate (IMN) prior to induction of labour - clinical trial with analyses of efficacy, cost effectiveness and acceptability.BMC Pregnancy Childbirth. 2006 Jul 25;6:25. doi: 10.1186/1471-2393-6-25. BMC Pregnancy Childbirth. 2006. PMID: 16869966 Free PMC article.
-
Early medical abortion with self-administered low-dose mifepristone in combination with misoprostol.J Obstet Gynaecol Res. 2018 Sep;44(9):1705-1711. doi: 10.1111/jog.13716. Epub 2018 Jul 5. J Obstet Gynaecol Res. 2018. PMID: 29974571 Free PMC article.
-
Antiprogestin pharmacodynamics, pharmacokinetics, and metabolism: implications for their long-term use.J Pharmacokinet Biopharm. 1997 Dec;25(6):647-72. doi: 10.1023/a:1025725716343. J Pharmacokinet Biopharm. 1997. PMID: 9697076 Review.
-
Feasibility of medication abortion self-care service delivery in Ghana.Reprod Health. 2025 May 2;22(1):64. doi: 10.1186/s12978-025-02021-1. Reprod Health. 2025. PMID: 40317063 Free PMC article.
-
Comparing the World Health Organization-versus China-recommended protocol for first-trimester medical abortion: a retrospective analysis.Int J Womens Health. 2012;4:123-7. doi: 10.2147/IJWH.S30354. Epub 2012 Mar 26. Int J Womens Health. 2012. PMID: 22505831 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Medical